指南与共识头颈部肿瘤放疗姑息放疗与转移瘤

COVID-19大流行期间风险适应性头颈癌放疗实践建议:ASTRO-ESTRO共识

Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement.
指南 / 共识 · Radiother Oncol · 2020-07-27

ASTRO与ESTRO针对COVID-19大流行期间头颈癌放疗资源受限情况,采用改良快速Delphi流程组织国际专家小组制定实践建议。小组评估早期与晚期两种大流行情景,就治疗优先级、感染期间放疗延迟或中断、剂量分割与化疗使用、手术管理及门诊随访调整等达成共识,旨在确保高质量头颈癌治疗延续。

要点

  • 共识覆盖治疗优先级、感染期间放疗延迟或中断、剂量分割与化疗使用等实践领域。
  • 采用改良快速Delphi流程,30名专家完成3轮调查,应答率100%。
  • 分别评估早期风险缓解与晚期资源严重减少两种大流行情景下的治疗建议。

核心结论

  • 该共识旨在COVID-19大流行期间资源受限和风险增高的情况下,确保高质量头颈癌治疗得以继续,以挽救生命并获得症状获益。

研究设计与样本

  • ASTRO、ESTRO及部分亚太国家国际专家小组完成改良快速Delphi流程,每轮调查在线开放24小时,下一轮在前一轮结束后24小时内启动。
  • 邀请31名专家,29名接受(94%),经替换后30名完成全部3轮调查(应答率100%)。
  • 采用强共识≥80%、共识≥66%的截断值,评估早期(风险缓解)和晚期(放疗资源严重减少)两种大流行情景,为5例头颈癌病例制定治疗建议。

主要发现

  • 在治疗优先级、是否因合并SARS-CoV-2感染延迟或中断放疗、各情景下放疗剂量分割方案与化疗使用、手术室关闭时外科病例管理、门诊预约与支持治疗调整等领域达成共识或强共识。

关键数值与推荐

  • 强共识截断值为≥80%,共识截断值为≥66%,均沿用RAND方法学。
  • 共评估5例头颈癌病例,制定对应治疗建议。

临床怎么用

  • 在COVID-19大流行资源受限期间,可参照本共识对头颈癌放疗进行风险适应性调整,包括治疗优先级排序、感染时放疗时机决策、剂量分割与化疗选择、手术安排及门诊随访调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff. METHODS AND MATERIALS: A panel of international experts from ASTRO, ESTRO, and select Asia-Pacific countries completed a modified rapid Delphi process. Topics and questions were presented to the group, and subsequent questions were developed from iterative feedback. Each survey was open online for 24 hours, and successive rounds started within 24 hours of the previous round. The chosen cutoffs for strong agreement (≥80%) and agreement (≥66%) were extrapolated from the RAND methodology. Two pandemic scenarios, early (risk mitigation) and late (severely reduced radiation therapy resources), were evaluated. The panel developed treatment recommendations for 5 HNC cases. RESULTS: In total, 29 of 31 of those invited (94%) accepted, and after a replacement 30 of 30 completed all 3 surveys (100% response rate). There was agreement or strong agreement across a number of practice areas, including treatment prioritization, whether to delay initiation or interrupt radiation therapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation dose-fractionation schedules and use of chemotherapy in each pandemic scenario), management of surgical cases in event of operating room closures, and recommended adjustments to outpatient clinic appointments and supportive care. CONCLUSIONS: This urgent practice recommendation was issued in the knowledge of the very difficult circumstances in which our patients find themselves at present, navigating strained health care systems functioning with limited resources and at heightened risk to their health during the COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC treatments continue, to save lives and for symptomatic benefit.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Thomson DJ, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiother Oncol. 2020. PMID: 32730830. doi:10.1016/j.radonc.2020.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。